fenofibrate vs rosuvastatin/ezetimibe
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of fenofibrate and rosuvastatin/ezetimibe. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Fenofibrates (e.g., fenofibrate and fenofibric acid) Clinical Impact: Fibrates may cause myopathy when given alone.
TriCor, Antara
Roszet
Fenofibrate is a medicine that helps lower bad cholesterol and fats (triglycerides) in your blood, while raising good cholesterol.
Roszet contains rosuvastatin, which is a statin medicine. It helps lower bad cholesterol and reduce the risk of heart problems.
This medicine is used with a diet to treat high cholesterol and high levels of triglycerides (fats) in the blood. It helps adults who have primary hypercholesterolemia or mixed dyslipidemia. It can also treat adults with severe hypertriglyceridemia. However, fenofibrate has not been proven to prevent heart disease in people with type 2 diabetes.
This medicine can help lower LDL cholesterol (bad cholesterol) if you have high cholesterol. It can also slow down the hardening of your arteries. Roszet can also lower triglycerides if you have high triglycerides.
Fenofibrate is a type of drug called a PPAR alpha agonist. It works by activating a protein in your body that helps break down fats and cholesterol. This leads to lower levels of bad cholesterol and triglycerides, and higher levels of good cholesterol.
Rosuvastatin blocks a substance your body needs to make cholesterol. This lowers the amount of cholesterol in your blood. It helps prevent heart attacks and strokes.
- • Abnormal liver function tests
- • Increased ALT (a liver enzyme)
- • Increased AST (a liver enzyme)
- • Increased CPK (a muscle enzyme)
- • Runny nose
- • Headache
- • Nausea
- • Muscle pain
- • Weakness
- • Constipation
- Nausea 2,912
- Fatigue 2,840
- Diarrhoea 2,681
- Dyspnoea 2,099
- Headache 2,058
- Tiredness 11,698
- Feeling sick to your stomach 10,037
- Difficulty breathing 9,212
- Loose stools 9,199
- Muscle pain 8,784
Fenofibrate can cause liver problems. Your doctor should check your liver function with blood tests before you start taking it and regularly while you are taking it. Stop taking fenofibrate and tell your doctor right away if you have signs of liver problems, such as yellowing of your skin or eyes, dark urine, or stomach pain. Fenofibrate can also cause muscle pain or weakness, especially if you are also taking a statin medicine. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness.
Rosuvastatin can sometimes cause muscle problems, including rhabdomyolysis. This can damage your kidneys. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor may do blood tests to check your liver.
It is not known if fenofibrate will harm an unborn baby. You should only use fenofibrate during pregnancy if your doctor decides that the benefit outweighs the risk. You should not breastfeed while taking fenofibrate.
Rosuvastatin can harm your unborn baby. Do not take this medicine if you are pregnant. Breastfeeding is also not recommended while taking rosuvastatin.
Also Compare, Nearby Drugs
Compare fenofibrate with
How to Read This fenofibrate vs rosuvastatin/ezetimibe Comparison
fenofibrate is classified in the Fibrate drug class, while rosuvastatin/ezetimibe sits within the Statin / Cholesterol Absorption Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, fenofibrate has 12,590 submissions while rosuvastatin/ezetimibe has 48,930. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these medications can both cause muscle problems on their own. using them at the same time makes it more likely that you will experience muscle damage.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for fenofibrate or rosuvastatin/ezetimibe.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.